文献速递浆细胞疾病淋巴瘤

多发性骨髓瘤与华氏巨球蛋白血症患者对SARS-CoV-2加强疫苗免疫原性的前瞻性研究

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.
PubMed 文献 · Blood Adv · 2025-01-01

前瞻性队列研究纳入多发性骨髓瘤(MM)93例和华氏巨球蛋白血症(WM)48例患者,基础接种后28天有效免疫应答(EIR,抗棘突抗体滴度>250 U/mL)率分别为47%和25%,第一和第二剂加强后分别升至84%和91%(MM)及60%和89%(WM)。MM中低丙种球蛋白血症、淋巴细胞减少、抗CD38单抗或糖皮质激素治疗与较低EIR相关;WM中布鲁顿酪氨酸激酶抑制剂或利妥昔单抗治疗与较低EIR相关。

要点

  • MM和WM患者基础SARS-CoV-2疫苗接种后EIR率分别为47%和25%。
  • 第一和第二剂加强后EIR率MM升至84%和91%,WM升至60%和89%。
  • MM中低丙种球蛋白血症、淋巴细胞减少、抗CD38单抗或糖皮质激素治疗与较低EIR相关。

核心结论

  • MM和WM患者对基础SARS-CoV-2疫苗系列体液应答受损,但重复加强疫苗显著改善免疫原性。

研究设计与样本

  • 前瞻性队列研究,纳入MM患者93例和WM患者48例,研究SARS-CoV-2疫苗接种。
  • 主要终点为基础疫苗系列接种后28天的有效免疫应答(EIR),即抗棘突SARS-CoV-2抗体滴度>250 U/mL。
  • 试验注册于www.ClinicalTrials.gov,编号NCT04830046。

主要发现

  • 基础疫苗系列后EIR率MM为47%,WM为25%。
  • 第一剂加强后EIR率MM为84%,WM为60%;第二剂加强后MM为91%,WM为89%。
  • MM中与较低EIR相关的因素为低丙种球蛋白血症、淋巴细胞减少、抗CD38单抗或糖皮质激素治疗。
  • WM中布鲁顿酪氨酸激酶抑制剂或利妥昔单抗治疗与较低EIR相关,无症状和未治疗患者EIR较高。
  • 与健康供者相比,MM和WM患者对野生型和变异型SARS-CoV-2(Alpha、Beta、Gamma)的抗体依赖性细胞吞噬、中性粒细胞吞噬和自然杀伤细胞活性降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with multiple myeloma (MM) and Waldenström macroglobulinemia (WM) have increased risk of severe coronavirus disease 2019. Impaired humoral responses to the primary vaccination series against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported in patients with MM and WM, but the impact of booster vaccinations and functional status of the elicited antibodies are unknown. We performed a prospective cohort study investigating SARS-CoV-2 vaccination in patients with MM (n = 93) and WM (n = 48). The primary end point was effective immune response (EIR) at 28 days after the primary vaccination series (ie, anti-spike SARS-CoV-2 antibody titer >250 U/mL). The EIR rate after the primary vaccination series was 47% and 25% in patients with MM and WM, respectively. After the first and second booster vaccinations, the EIR rates increased to 84% and 91% in patients with MM and 60% and 89% in those with WM, respectively. Factors associated with lower EIR in patients with MM were hypogammaglobulinemia, lymphopenia, and treatment with anti-CD38 monoclonal antibody or corticosteroid. In patients with WM, treatment with a Bruton tyrosine kinase inhibitor or rituximab was associated with a lower EIR, whereas asymptomatic and treatment-naïve patients had a higher EIR. Functional profiling identified reduced antibody-dependent cellular phagocytosis, neutrophil phagocytosis, and natural killer cell activity against wild-type and variant SARS-CoV-2 (Alpha, Beta, and Gamma) in patients with MM and WM compared to healthy donors. Our data demonstrate that although patients with MM and WM have impaired humoral responses to the primary SARS-CoV-2 vaccination series, repeated booster vaccines significantly improve immunogenicity. This trial was registered at www.ClinicalTrials.gov as #NCT04830046.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Branagan AR, Mo C, Lei M, et al. Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia. Blood Adv. 2025. PMID: 40472329. doi:10.1182/bloodadvances.2025016513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。